Scholar Rock Holding (SRRK) Short-term Investments (2017 - 2026)
Scholar Rock Holding's quarterly Short-term Investments came in at $49.4 million in Q1 2026, down 78.18% year-on-year from $226.4 million in Q1 2025, and up 12.18% quarter-over-quarter from $44.0 million in Q4 2025.
Scholar Rock Holding has reported Short-term Investments for 10 years, with the latest figure at $49.4 million in Q1 2026.
- For the quarter ending Q1 2026, Short-term Investments fell 78.18% year-over-year to $49.4 million; the trailing twelve-month figure through Mar 2026 stood at $49.4 million (down 78.18% YoY), and the FY2025 full-year result was $44.0 million, down 83.02% from the prior year.
- Short-term Investments for Q1 2026 stood at $49.4 million, up from $44.0 million in the prior quarter.
- The five-year high for Short-term Investments was $259.4 million in Q4 2024, with the low at $44.0 million in Q4 2025.
- Average Short-term Investments over 5 years is $135.4 million, with a median of $140.7 million recorded in 2023.
- Year-over-year, Short-term Investments jumped 428.12% in 2022 and slumped 83.02% in 2025.
- Tracing SRRK's Short-term Investments over 5 years: stood at $212.1 million in 2022, then fell by 16.03% to $178.1 million in 2023, then surged by 45.66% to $259.4 million in 2024, then tumbled by 83.02% to $44.0 million in 2025, then advanced by 12.18% to $49.4 million in 2026.
- The last three Short-term Investments figures came in at $49.4 million (Q1 2026), $44.0 million (Q4 2025), and $82.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.40 Mn |
| Dec 31, 2025 | 44.04 Mn |
| Sep 30, 2025 | 82.86 Mn |
| Jun 30, 2025 | 142.09 Mn |
| Mar 31, 2025 | 226.45 Mn |
| Dec 31, 2024 | 259.40 Mn |
| Sep 30, 2024 | 62.67 Mn |
| Jun 30, 2024 | 97.12 Mn |
| Mar 31, 2024 | 146.45 Mn |
| Dec 31, 2023 | 178.08 Mn |
| Sep 30, 2023 | 151.04 Mn |
| Jun 30, 2023 | 140.67 Mn |
| Mar 31, 2023 | 124.00 Mn |
| Dec 31, 2022 | 212.09 Mn |
| Sep 30, 2022 | 210.58 Mn |
| Jun 30, 2022 | 64.96 Mn |
| Mar 31, 2022 | 110.04 Mn |
| Dec 31, 2021 | 40.16 Mn |
| Sep 30, 2021 | 70.30 Mn |
| Jun 30, 2021 | 75.30 Mn |
| Mar 31, 2021 | 155.58 Mn |
| Dec 31, 2020 | 180.67 Mn |
| Sep 30, 2020 | 60.04 Mn |
| Jun 30, 2020 | 26.05 Mn |
| Mar 31, 2020 | 65.21 Mn |
| Dec 31, 2019 | 121.14 Mn |
| Sep 30, 2019 | 143.44 Mn |
| Jun 30, 2019 | 71.33 Mn |
| Mar 31, 2019 | 92.66 Mn |
| Dec 31, 2018 | 60.58 Mn |
| Dec 31, 2017 | 1.50 Mn |